NBA to Let Players Invest in Cannabis Industry and Promote Brands with New Deal
The NBA is giving players the option to invest in the cannabis industry under a new deal.
Cannabis is officially being removed from the National Basketball Association’s (NBA) banned substances list for players. Another slam dunk for cannabis is that the association plans to let those players promote and invest in cannabis companies (1).
The new seven-year agreement also plans to formally remove drug testing requirements for cannabis. For the past three seasons, the NBA has considered the testing requirement to be temporarily suspended.
“We decided that, given all the things that were happening in society, given all the pressures and stress that players were under, that we didn’t need to act as Big Brother right now,” Adam Silver, NBA Commissioner, commented on in the past. “I think society’s views around marijuana has changed to a certain extent.”
Details about the Collective Bargaining Agreement between the NBA and National Basketball Players Association will not be released until a term sheet is finalized.
Reference
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Khan
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
